Evidence map›Paper›PMID 35513865›Full record

ArticleBMC pulmonary medicine2022

Analysis of the association of ANO3/MUC15, COL4A4, RRBP1, and KLK1 polymorphisms with COPD susceptibility in the Kashi population.

Lifeng Tang, Xuemei Zhong, Hui Gong, Maimaitiaili Tuerxun, Tao Ma, Jie Ren, Chengxin Xie, Aifang Zheng, Zulipikaer Abudureheman, Ayiguzali Abudukadeer and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Lifeng Tang *Department of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Xuemei Zhong *Department of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Hui GongClinical Research Center of Infectious Diseases (Pulmonary Tuberculosis), First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Maimaitiaili TuerxunDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Tao MaDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Jie RenDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Chengxin XieDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Aifang ZhengDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Zulipikaer AbudurehemanClinical Research Center of Infectious Diseases (Pulmonary Tuberculosis), First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Ayiguzali AbudukadeerDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Paierda AiniDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Subinuer YilamujiangClinical Research Center of Infectious Diseases (Pulmonary Tuberculosis), First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China.
Li LiDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, 844000, Xinjiang, People's Republic of China. lili5511@yeah.net.
People's Hospital of Xinjiang Uygur Autonomous Region · CNQujiang People's Hospital · CN

Funding

Tianshan Youth Project of Xinjiang Uyghur Autonomous Region 2019Q143Xinjiang Uygur Autonomous Natural Science Foundation of China under Grant 2017D01C016
6 · The paper itself

Abstract

objectiveChronic obstructive pulmonary disease (COPD) is a complex, multifactorial, polygenic disease. The rate of occurrence of COPD in the Kashi population (Uyghur) is significantly higher than that observed nationwide. The identification of COPD-related genes in the Chinese Uyghur population could provide useful insights that could help us understand this phenomenon. Our previous whole-exome sequencing study of three Uyghur families with COPD demonstrated that 72 mutations in 55 genes might be associated with COPD; these included rs15783G > A in the anoctamin 3 (ANO3) gene/mucin 15 (MUC15) gene, rs1800517G > A in the collagen type IV alpha 4 chain (COL4A4) gene, rs11960G > A in the ribosome binding protein 1 (RRBP1) gene, and rs5516C > G in the kallikrein 1 (KLK1) gene. This case-control study aimed to further validate the association of the four mutations with COPD in the Chinese Uyghur population.

methodsSanger sequencing was used for the genotyping of four polymorphisms (ANO3/MUC15 rs15783, COL4A4 rs1800517, RRBP1 rs11960, and KLK1 rs5516) in 541 unrelated Uyghur COPD patients and 534 Uyghur healthy controls. We then conducted stratified analyses based on the smoking status and airflow limitation severity, to explore the correlation between selected gene polymorphisms and COPD.

resultsANO3/MUC15 rs15783 and KLK1 rs5516 polymorphisms could significantly reduce COPD risk (p < 0.05), but COL4A4 rs1800517 and RRBP1 rs11960 polymorphisms were not correlated with COPD in the entire population. In a stratified analysis of smoking status, non-smokers with the ANO3/MUC15 rs15783G/G genotype (OR = 0.63, p = 0.032) or COL4A4 rs1800517 allele G (OR = 0.80, p = 0.023) had a reduced risk of COPD. Smokers with the RRBP1 rs11960A/G genotype had a lower risk of COPD (OR = 0.41, p = 0.025). The KLK1 rs5516G > C polymorphism was associated with a decreased risk of COPD (OR < 1, p < 0.05), irrespective of the smoking status of individuals. No significant association with COPD severity was observed in individuals with these four polymorphisms (p > 0.05).

conclusionWe identified four previously unreported mutations (ANO3/MUC15 rs15783, COL4A4 rs1800517, RRBP1 rs11960, and KLK1 rs5516) that might decrease the COPD risk in individuals with different smoking statuses in the Chinese Uyghur population. Our findings provide new light for the genetic risk factors associated with the occurrence of COPD.

Indexed as

Genetic Predisposition to DiseasePulmonary Disease, Chronic ObstructiveAnoctaminsCase-Control StudiesChinaCollagen Type IVGene FrequencyGenotypeHumansMucinsPolymorphism, Single NucleotideTissue KallikreinsANO3 protein, humanAnoctaminsCOL4A4 protein, humanCollagen Type IVMUC15 protein, humanMucinsTissue KallikreinsANO3/MUC15Chronic obstructive pulmonary diseaseCOL4A4Genetic polymorphismKLK1RRBP1Smoking status

Identifiers

PMID35513865
PMCPMC9074245
OpenAlexW4229010822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.